Pharmaceutica
Sultana et al., Pharm Anal Acta 2013, S2
http://dx.doi.org/10.4172/2153-2435.S2-004
Analytica Acta
Research Article
Open Access
Facile and Manifest Liquid Chromatographic Method for the Simultaneous
Determination of Enalpril Maleate and NSAIDs in API and Pharmaceutical
Formulations
Najma Sultana1, Saila Naveed2,3* and M Saeed Arayne1
Research Institute of Pharmaceutical Sciences Faculty of Pharmacy, University of Karachi, Karachi, Pakistan
Jinnah University for Women, Karachi, Pakistan
3
Department of Chemistry, University of Karachi, Karachi, Pakistan
1
2
Abstract
Patients diagnosed with hypertension are prescribed an large number of medications for appropriate therapy,
increasing risk of side effects or drug interactions. Enalapril, ACE inhibitor is commonly used as a drug of choice
for the treatment of hypertension. On the other hand, NSAIDs are generally used for the treatment of pain, fever
and inlammation, particularly in arthritis. A simple, eficient, economical and least time consuming isocratic method
for the simultaneous determination of enalapril (ENP) and non-steroidal anti-inlammatory drugs (lurbiprofen,
diclofenac sodium, ibuprofen and mefanamic) in bulk, pharmaceutical formulations and human serum using high
performance liquid chromatography (HPLC) has been developed and validated. ENP was separated from NSAIDs
using a Purospher STAR C18 column (250×4.6 mm, 5 μm) and a mobile phase consisting of methanol, water (80:20,
v/v, pH was adjusted by ortho phosphoric acid to 2.8 at a low rate of 1.8 mL min-1 and at ambient temperature.
Efluents from the column were monitored at 225 nm. The retention time of ENP was 4.1 minute and that for
lurbiprofen, diclofenac sodium, ibuprofen and mefanamic acid was 5.4, 5.9, 6.4 and 8.7 mins respectively. LLOD
and LLOQ of enalapril were 0.7 and 2.2 ng ml-1 respectively and that of lurbiprofen, diclofenac sodium, ibuprofen
and mefanamic were 0.24, 0.07, 0.1, 0.1 and 0.7, 0.2, 0.3 and 0.4 ng ml-1 respectively. The method was validated
according to ICH guidelines. Linearity of the method was studied in the concentration range 2.5-100 µg mL-1 for ENP
and 0.625-25 µg mL-1 for (NSAIDs) where it demonstrated good linearity with r=0.9995, 0.9979, 0.9995, 0.9967,
0.9967 and 0.9995 (n=6), respectively, recovery was >97.8%. The developed method may successfully be applied
for the quantitative analysis of ENP and NSAIDs alone or in combination from raw materials, in bulk drugs, dosage
formulations and in serum.
Keywords: Enalpril maleate; Flurbiprofen; Diclofenac sodium;
Ibuprofen, Mefenamic acid, RP-HPLC
CH2CH2CHNHCH
Introduction
Enalapril maleate is chemically described as (S)-1-[N-[1(ethoxycarbonyl) -3-phenylpropyl]-L-alanyl] -L-proline, (Z)-2butenedioate salt (Figure 1) [1]. It is an ester prodrug which is
hydrolyzed to pharmacologically active enalaprilate, a speciic
competitive inhibitor of ACE, It inhibits the active sites of a zinc
glycoprotein, the angiotensin converting enzyme (ACE) blocking the
conversion of angiotensin I to angiotensin II, whose levels are elevated
in patients with hypertension [2].
Hypertension and musculoskeletal are two common coexisting
problems for which antihypertensive and analgesics as nonsteroidal
anti-inlammatory drugs (NSAIDs) are most commonly prescribed
together [3]. Over the last two decades, concern about probable
drug interactions between NSAIDs and antihypertensive agents has
been grown. Cases with hypertensive emergency have been reported
ater taking NSAIDs in patients with previously well-controlled
hypertension [4,5]. Various HPLC methods have been reported for
estimation of enalapril maleate [6-7]. Several methods have also been
reported for determination of NSAIDs [8-10].
Our research group has developed and validated simultaneous
methods for the co-adminstered drugs as rosuvastatin with NSAIDs
[11] and with alprazolam and diclofenac [12]. Lisinopril, captopril
[13,14] and metformin [15] have also been simultaneously determined
with NSAIDs. Sultana and Arayne et al., have also developed methods
for the simultaneous determination of various co-administered
drugs as calcium channel blockers with NSAIDS [16,17] and many
other drugs [18-23] in raw materials, pharmaceutical formulations
Pharm Anal Acta
.
CH3
CO
COOCH2CH3
N
COOH
CHCOOH
CHCOOH
Enalapril
AR
R
O
C
C
Where
R=H, CH3 or alkyl
AR= aryl or Heteroaryl
OH
H
aryl alkanoic acid
Figure 1: Aryl alkanoic acid.
*Corresponding author: Saila Naveed, Jinnah University for Women, Karachi,
Pakistan, E-mail: saila117@yahoo.com
Received May 06, 2013; Accepted May 25, 2013; Published May 27, 2013
Citation: Sultana N, Naveed S, Arayne MS (2013) Facile and Manifest Liquid
Chromatographic Method for the Simultaneous Determination of Enalpril Maleate
and NSAIDs in API and Pharmaceutical Formulations. Pharm Anal Acta S2: 004.
doi:10.4172/2153-2435.S2-004
Copyright: © 2013 Sultana N, et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and
source are credited.
Pharmaceutical Formulations:
Regulatory updates
ISSN: 2153-2435 PAA, an open access journal
Citation: Sultana N, Naveed S, Arayne MS (2013) Facile and Manifest Liquid Chromatographic Method for the Simultaneous Determination of Enalpril
Maleate and NSAIDs in API and Pharmaceutical Formulations. Pharm Anal Acta S2: 004. doi:10.4172/2153-2435.S2-004
Page 2 of 5
and serum. All these developed and validated methods follow ICH
guidelines [23] are economical, short time consuming and could
be applied to quantitate drugs upto nano gram levels and thus ind
applications not only in pharma industry but also in clinical and
forensic laboratories as well as for pharmacokinetic studies. So keeping
in mind the above facts and as no RP-HPLC method is reported for
simultaneous estimation of enalapril and NSAIDs we made an attempt
to develop and validate a simple economical and time efective method
for the simultaneous quantiication of enalapril and four NSAIDs in
raw material, pharmaceutical formulations and serum. As the LLOD
is quite low and the drug could be detected in nano amounts in serum
this method is applicable for clinical and forensic laboratories.
concentrations of 2.5, 5, 10, 25, 50, 100 μg ml-1 of EM and 0.625, 1.25,
2.5, 6.25, 12.5 and 25 μg ml-1 of NSAIDs. Standard solutions (n=6) were
injected through 20 μl loop system and chromatograms were obtained
using 1.0 ml min-1 low rate. he eluent was monitored at 225 nm.
Calibration curve was constructed by plotting average peak area against
concentration and regression equation was computed, chromatogram
is depicted in igure 2.
Materials and Methods
Sample preparation
Chemicals and reagents
To determine the content of the drugs in pharmaceutical
formulations, 20 tablets of each formulation were powdered and
an amount equivalent to 10 mg of EM and 2.5 mg of NSAIDs was
transferred to 100 mL volumetric lask, 50 ml of mobile phase was
added and the lask was kept in an ultrasonic bath for 10 mins. he
resulting solutions were iltered through a 0.45 μm ilter paper and
diluted to the desired concentration and analyzed for the drug content,
chromatogram is depicted in igure 3.
HPLC grade methanol and phosphoric acid were obtained from
Merck, Germany. Enalapril was a git from Brooks Pharmaceutical
Laboratories Pakistan. he NSAIDs used were diclofenac sodium from
Yung Shin Pharmaceutical Ind. Co. Ltd, lurbiprofen and ibuprofen,
Abbott Laboratories (Pakistan) Ltd and mefenamic acid from Parke
Davis and Co. Ltd. Dosage forms of diclofenac sodium (Voren 50
mg), lurbiprofen (NSAID 100mg), ibuprofen (Brufen 200 mg) and
mefenamic acid (Ponstan 250 mg) were purchased from the local
pharmacy. All these drugs had an expiry of not less than one year at
the time of study.
Validation of the method
he developed method was validated in terms of linearity, accuracy,
speciicity, limit of detection, limit of quantiication, intra-day and
inter-day precision and repeatability of measurement.
mV
40
Instrumentation
Two identical LC systems of two diferent labs were used for the
separation in order to ensure ruggedness of the method. Shimadzu
HPLC system consisted of LC-10 AT VP pump, DGU-14 AM on-line
degasser, rheodyne manual injector itted with a 20 μL loop, and SPD10 A VP UV–VIS detector and a Purospher star C18 (5 µm, 25×0.46
cm) column was utilized for separation. Chromatographic system
was integrated via Shimadzu model CBM-102 Communication Bus
Module to P-IV computer loaded with CLASS-GC sotware (Version
5.03) for data acquisition and mathematical calculations.
a
b
20
c
he mobile phase containing methanol: water (80:20), pH was
adjusted to pH 2.5 with orthophosphoric and iltered through 0.45
micron membrane ilter and then ultrasonicated for 10 mins. he low
rate was set to 1.0 ml min-1.
5
10
15
min
Figure 2: A representative chromatogram of (a) enalapril (b) lurbiprofen (c)
diclofenac sodium (d) ibuprofen and (e) mefanimic acid in raw material.
mV
Preparation of stock solutions
Stock solutions of 100 μg mL-1 of enalapril, ibuprofen, lurbiprofen,
diclofenac sodium and mefenamic acid were prepared individually
by dissolving 10 mg of each drug in 100 mL volumetric lask using
mobile phase as a diluent. Aliquots were diluted in the range of 0.62525 μg mL-1 for ibuprofen, diclofenac sodium, mefenamic acid and
lurbiprofen and for enalapril 2.5-100 μg mL-1 for. hese solutions
were stored at 20ºC, they were prepared once and analyzed daily for
inter-day and inter-operator variations of the method, 20 µL of these
solutions were injected into LC system and chromatographed.
e
0
0
Chromatographic conditions
d
a
100
b
c
d
e
0
Calibration curve
Calibration curves were prepared by taking appropriate aliquots of
standard EM and NSAIDs stock solutions in diferent 10 ml volumetric
lask and diluted up to the mark with mobile phase to obtain inal
Pharm Anal Acta
0
5
10
mn
Figure 3: A representative chromatogram of (a) enalapril (b) lurbiprofen (c)
diclofenac sodium (d) ibuprofen and (e) mefanamic acid in formulation.
Pharmaceutical Formulations:
Regulatory updates
ISSN: 2153-2435 PAA, an open access journal
Citation: Sultana N, Naveed S, Arayne MS (2013) Facile and Manifest Liquid Chromatographic Method for the Simultaneous Determination of Enalpril
Maleate and NSAIDs in API and Pharmaceutical Formulations. Pharm Anal Acta S2: 004. doi:10.4172/2153-2435.S2-004
Page 3 of 5
Results and Discussion
his work was designed to develop an isocratic method based
on RP-HPLC separation combined with UV detection for ENP and
NSAIDs assay in API and pharmaceuticals dosage formulations.
he goal of this study was to develop a rapid, more accurate, precise,
reliable, least time consuming HPLC method for the drugs individually
as well as simultaneously. his analytical method was developed
taking in account the therapeutic concentrations range and overdose
concentrations range, has been validated and holds well for the
determination of drug in raw materials and dosage formulations.
Our research group has been involved in the developments of new
and eicient RP-HPLC methods for the determination of drugs alone
as well as simultaneous determination of co-adminstered drugs. As in
these methods the drug could be quantitated upto nanogram levels
so they can also be applied for clinical laboratories, serums as well as
forensic medicines.
To develop a precise, accurate and suitable RP- HPLC method
for the simultaneous estimation of EM and NSAIDs, diferent mobile
phases ratios (50:50, 60:40, 70:30, 80:20 v/v) of methanol: water were
tried and the best selected mobile phase was 80:20 methanol: water.
he pH of the mobile phase was adjusted with orthophosphoric acid
and tried in the range 2 to 3 where the best tailing results were obtained
with pH 2.8. he proposed chromatographic conditions were found to
be appropriate for the quantitative determination. he short analysis
time (<10 min) also enables its application in routine and qualitycontrol analysis of inished products.
Method validation
he proposed HPLC method was validated as per ICH guidelines
[21]. Where speciicity, linearity, accuracy, precision, robustness
and ruggedness were studied which were well in accordance to ICH
guidelines.
Speciicity: he peak purity of EM and NSAIDs was assessed by
comparing the retention time (RT) of standard EM and NSAIDs. Good
correlation was obtained between the retention time of standard and
sample of EM and NSAIDs.
Linearity: Linearity was studied by preparing standard solutions at
diferent concentration levels. he linearity range for EM and NSAIDs
was found to be 2.5- 100 μg ml-1 and 0.625-25 μg ml-1, respectively. he
regression equation for EM and NSAIDs is given in table 1.
Accuracy (Recovery studies): To check the degree of accuracy of
the method, recovery studies were performed in triplicate by standard
addition method at 80%, 100% and 120%. Known amounts of standard
EM and NSAIDs were added to pre-analyzed samples and were
subjected to the proposed HPLC method. Results of recovery studies
are shown in table 2.
Precision: Precision was evaluated by carrying out six independent
sample preparations of a single lot of formulation. he sample solution
was prepared in the same manner as described in sample preparation.
Percentage relative standard deviation (%RSD) was found to be less
than 2% for within a day and day to day variations, which proves that
method is precise. Results are shown in table 3.
Sensitivity: he lower limit of quantitation (LLOQ) of the
method as signal/noise of enalapril, diclofenac acid, mefenamic acid,
lurbiprofen and ibuprofen was found to be 2.2, 0.7, 0.2, 0.3 and 0.4
Pharm Anal Acta
ng mL-1 respectively. Similarly a signal/noise of 3, a LOD of enalapril,
diclofenac acid, mefenamic acid,lurbiprofen and ibuprofen was
determined to be 0.7, 0.24, 0.07, 0.1 and 0.1 ng mL-1, respectively.
Ruggedness: Ruggedness of this method was evaluated in two
diferent labs with two diferent instruments. Lab 1 was in the Research
Institute of Pharmaceutical Sciences, Faculty of Pharmacy University
of Karachi, while Lab 2 was in the Department of Chemistry, Faculty of
Science, University of Karachi. he method did not show any notable
deviations in results from acceptable limits.
Robustness of method: To evaluate the robustness of the developed
RP-HPLC method, small deliberate variations in the optimized method
parameters were done. he efect of change in low rate, pH and mobile
phase ratio on the retention time and tailing factor were studied. he
method was found to be unafected by small changes like ± 0.1 change
in pH, ± 0.1 change in low rate and ± 1 change in mobile phase (Table
4).
Conclusion
he proposed RP-HPLC method allows for accurate, precise and
reliable measurement of EM and NSAIDs simultaneously in combined
dosage form within a short time. he developed RP-HPLC method was
found to be simple, rapid, selective, accurate, precise and economical
for the concurrent estimation of drugs in multiple drugs therapy of EM
and NSAIDs. he RSD for all parameters was found to be less than one,
which indicates the validity of method and assay results obtained by
this method are in fair agreement. he developed method can be used
for routine quantitative simultaneous estimation of EM and NSAIDs
in multicomponent pharmaceutical preparation as well as in clinical
laboratories.
LLOQ**
(ngmL-1)
Regression
equation
Conc.
(µgmL-1)
0.7
2.2
A= 2340.4x +3022.3
2.5-100
0.24
0.7
A=9368.9x +5785.8
0.625-25
0.07
0.2
A=18339x + 10493
0.625-25
Flurbiprofen 0.9967
0.1
0.3
A=12964x + 4896.7
0.625-25
Ibuprofen
0.1
0.4
A=9171.4x + 4741
0.625-25
Drugs
r2
Enalapril
0.9995
Diclofenac
sodium
0.9995
Mefanimic
acid
0.9967
0.9995
*Lower limit of detection, **Lower limit of quantiication
Table 1: Regression statistics LLOD and LLOQ.
Drugs
Enalapril
Diclofenac sodium
Mefanamic acid
Flurbiprofen
Ibuprofen
Pharmaceutical Formulations:
Regulatory updates
Conc
%RSD
80%
0.01
% Recovery
99.96
100%
0.00
100.00
120%
0.00
99.98
80%
0.01
99.94
100%
0.00
100.09
120%
0.00
100.00
80%
0.00
100.03
100%
0.00
100.00
120%
0.00
100.00
80%
0.01
99.89
100%
0.00
99.97
120%
0.00
99.95
80%
0.01
99.85
100%
0.00
99.96
120%
0.00
99.96
Table 2: Accuracy in formulations.
ISSN: 2153-2435 PAA, an open access journal
Citation: Sultana N, Naveed S, Arayne MS (2013) Facile and Manifest Liquid Chromatographic Method for the Simultaneous Determination of Enalpril
Maleate and NSAIDs in API and Pharmaceutical Formulations. Pharm Anal Acta S2: 004. doi:10.4172/2153-2435.S2-004
Page 4 of 5
Drugs
Enalapril
Diclofenac
sodium
Mefanamic acid
Flurbiprofen
Ibuprofen
Conc. injected
Inter-day
µg mL−1
%RSD %Recovery
Intra-day
%RSD
%Recovery
2.5
0.0073
99.93
0.08
99.9
5
0.0078
100.02
0.09
100.0
10
0.0019
100.06
0.07
100.1
25
0.001
100.17
0.062
100.2
50
0.0005
99.99
0.059
100.0
100
0.0002
100.10
0.089
1001.7
0.625
0.0121
99.88
0.095
99.9
1.25
0.0067
99.94
0.64
99.9
2.5
0.0017
99.99
0.098
100.0
6.25
0.0008
99.99
0.12
100.0
12.5
0.0004
99.99
0.89
100.0
25
0.0002
100.00
0.032
100.0
0.625
0.004
101.12
0.48
101.1
1.25
0.0039
100.03
0.098
100.0
2.5
0.001
100.01
0.089
100.0
6.25
0
99.91
0.5
99.9
12.5
0.0002
100.01
0.045
100.0
25
0
100.00
0
100.0
0.625
0.0077
99.87
0.09
99.9
1.25
0.0106
99.86
0.01
99.9
2.5
0.0014
99.97
0.089
100.0
6.25
0.0012
99.99
0.089
100.0
12.5
0.0004
99.97
0.58
100.0
25
0.0004
100.00
0.99
100.0
0.625
0.0133
99.72
0.98
99.7
1.25
0.0069
99.86
0.00689
99.9
2.5
0.002
100.03
0.08
100.0
6.25
0.001
99.93
0.9
99.9
12.5
0.0005
100.02
0.089
100.0
25
0.0002
100.00
0.04
100.0
Table 3: Inter day and intraday precision of enalapril and NSAIDs.
Level
K’
T
(Rs)
A: pH of mobile phase
2.0
-0.2
4.8
1.39
2.4
2.5
0
4.5
1.43
2.3
3.0
0.2
4.2
1.4
2.2
4.5 ± 0.3
1.43 ± 0.020
2.3 ± 0.1
Mean ± S.D (n=6)
B: Flow rate (mLmin-1)
0.8
-0.2
4.1
1.45
2.32
1
0
4.2
1.45
2.36
1.2
0.2
4.4
1.42
2.37
4.3 ± 0.212
1.44 ± 0.015
2.36 ± 0.026
Mean ± S.D (n=6)
C: Percentage of water in mobile phase (V/V)
25
-5
4.6
1.42
2.38
20
0
4.3
1.43
2.36
15
5
4.5
1.46
2.33
4.36 ± 0.070
2.36 ± 0.025
2.36 ± 0.025
Mean ± S.D (n=6)
C: Wavelength (nm)
220
-5
4.5
1.42
2.38
225
0
4.3
1.43
2.36
230
5
4.4
1.45
2.32
4.3 ± 0.070
1.43 ± 0.015
2.36 ± 0.030
Mean ± S.D (n=6)
K’= Capacity factors, N = Theoretical plates, T = Tailing factor
Rs=Resolution
Table 4: Robustness of the method.
Pharm Anal Acta
References
1. Sweetman SC (2005) Martindale: The Complete Drug Reference. (34thedn)
Pharmaceutical Press, London & Chicago 900-901.
2. Dominic PI, Gerald SB (1987) Analytical Proiles of Drug Substances. Academic
Press, New York, pages 207-243.
3. Oates JA (1988) Antagonism of antihypertensive drug therapy by nonsteroidal
anti-inlammatory drugs. Hypertension 11: II4-6.
4. Mousavy SM (1991) Indomethacin induces hypertensive crisis in preeclampsia
irrespective of prior antihypertensive drug therapy. Am J Obstet Gynecol 165:
1577.
5. Sultana N, Arayne MS, Naveed S, Shamshad H (2009) An RP-HPLC method
for simultaneous analysis and interaction studies on enalapril maleate and H2receptor antagonists. Acta Chromatographica 21: 547–558.
6. Yoon KH, Kim W, Park J, Kim HJ (2004) Determination of enalapril in human
plasma by high-performance liquid chromatography- electrospray ionization
mass spectrometry. Bull Korean Chem Soc 25: 878-880.
7. Ferretti R, Gallinella B, La Torre F, Villani C (1995) Direct high-performance
liquid chromatography resolution on chiral columns of tiaprofenic acid and
related compounds in bulk powder and pharmaceutical formulations. Journal of
Chromatography A 704: 217-223.
8. Niopas I, Mamzoridi K (1994) Determination of indomethacin and mefenamic
acid in plasma by high-performance liquid chromatography. J Chromatogr B
Biomed Appl 656: 447-450.
9. Staiej A, Pyrzynska K, Regan F (2007) Determination of anti-inlammatory
drugs and estrogens in water by HPLC with UV detection. J Sep Sci 30: 985991.
10. Sultana N, Arayne MS, Tabassum A (2012) Simultaneous quantitation and
monitoring of rosuvastatin with NSAIDs by liquid chromatography with UVdetection. Research and Reports in Medicinal Chemistry 2: 19-29.
11. Sultana N, Arayne MS, Ali SA (2013) An ultra-sensitive LC method for
simultaneous determination of rosuvastatin, alprazolam and diclofenic sodium
in API, pharmaceutical formulations and human serum by programming the
detector. Journal of Anal and Bioanal Techniques 3: 154.
12. Sultana N, Arayne MS, Siddiqui R, Naveed S (2012) RP-HPLC method for the
simultaneous determination of lisinopril and NSAIDs in API, pharmaceutical
formulations and human serum. American Journal of Analytical Chemistry 3:
147-152.
13. Sultana N, Arayne MS, Naveed S (2010) Simultaneous quantitation of captopril
and NSAIDs in API, dosage formulations and human serum by RP-HPLC. J
Chinese Chemical Society 57: 62-67.
14. Arayne MS, Sultana N, Zuberi H, Haroon U (2010) In vitro studies of interaction
between metformin and NSAIDs (non steroidal anti-inlamatory drugs) using
spectrophotometry and RP-high performance liquid chromatography. J Chil
Chem Soc 55: 206-211.
15. Sultana N, Arayne MS, Shai N, Siddiqui FA (2010) Simultaneous RPLC analysis of diltiazem and non-steroidal anti-inlammatory drugs in
pharmaceutical formulations and human serum. Chromatographia 71: 71-77.
16. Sultana N, Arayne MS, Waheed A (2011) Method Development of Verapamil
in Presence of NSAIDs using RP-HPLC Technique. Bull Korean Chem Soc
32: 2274-2278.
17. Sultana N, Arayne MS, Ali SA (2013) An ultra-sensitive LC method for the
simultaneous determination of paracetamol, carbamazepine, losartan and
ciproloxacin in bulk drug, pharmaceutical formulation and human serum by
programming the detector. AJAC 4: 24-33.
18. Gul S, Sultana N, Arayne MS, Shamim S, Akhtar M (2012) New method
for Optimization and simultaneous determination of sparloxacin andnNon
steroidal anti-Inlammatory Drugs: Its In-Vitro Application. American Journal of
Analytical Chemistry 328-337.
19. Sultana N, Arayne MS, Naveed S (2011) Simultaneous determination of
enalapril and statins in pharmaceutical formulation by RP-HPLC. J Chillean
Chemical Society 56: 734-737.
20. Siddiqui FA, Arayne MS, Sultana N, Qureshi F (2011) Development
and validation of stability-indicating HPLC method for the simultaneous
determination of paracetamol, tizanidine, and diclofenac in pharmaceuticals
and human serum. J AOAC Int 94: 150-158.
Pharmaceutical Formulations:
Regulatory updates
ISSN: 2153-2435 PAA, an open access journal
Citation: Sultana N, Naveed S, Arayne MS (2013) Facile and Manifest Liquid Chromatographic Method for the Simultaneous Determination of Enalpril
Maleate and NSAIDs in API and Pharmaceutical Formulations. Pharm Anal Acta S2: 004. doi:10.4172/2153-2435.S2-004
Page 5 of 5
21. Arayne MS, Sultana N, Tabassum A, Ali SN, Saila Naveed S (2012)
Simultaneous LC determination of rosuvastatin, lisinopril, captopril and
enalapril in API, formulations and human serum by liquid chromatography.
Medicinal Chemistry Research.
22. Arayne MS, Sultana N, Zuberi MH, Siddiqui FA (2013) Simultaneous RP-HPLC
method for thedDetermination of metformin, captopril, lisinopril and enalapril:
Its applications indDosage formulations and in human plasma. Medicinal
Chemistry Research.
23. International Conference on the Harmonization of Technical Requirements for
the Registration of Pharmaceuticals for Human Use (ICH) Q2B 1996 Validation
of Analytical Procedures, Methodology.
Submit your next manuscript and get advantages of OMICS
Group submissions
Unique features:
Citation: Sultana N, Naveed S, Arayne MS (2013) Facile and Manifest Liquid
Chromatographic Method for the Simultaneous Determination of Enalpril
Maleate and NSAIDs in API and Pharmaceutical Formulations. Pharm Anal
Acta S2: 004. doi:10.4172/2153-2435.S2-004
This article was originally published in a special issue, Pharmaceutical
Formulations: Regulatory updates handled by Editor(s). Dr. Preveen
Hiremath, Pharmaceutics International Inc., USA
Pharm Anal Acta
•
•
•
User friendly/feasible website-translation of your paper to 50 world’s leading languages
Audio Version of published paper
Digital articles to share and explore
•
•
•
•
•
•
•
•
250 Open Access Journals
20,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientiic Credits
Better discount for your subsequent articles
Special features:
Submit your manuscript at: www.omicsonline.org/submission
Pharmaceutical Formulations:
Regulatory updates
ISSN: 2153-2435 PAA, an open access journal